ROGER POMERANTZ
Board director at VerImmune · Director at Rubius Therapeutics · Executive at Seres Therapeutics
New York City Metropolitan Area
Find your path to ROGER
322 people in our graph share verified history with ROGER — schools, employers, funds. One of them is your warm intro.
Anika GuptaunlockedROGER: together at Flagship Pioneering (2017–2018)
×5ROGER: together at Massachusetts Institute of Technology
×3ROGER: together at Flagship Pioneering
ROGER: together at Harvard Medical School
About
Roger Pomerantz is a member of the board of directors at 1E Therapeutics and has held roles at Tibotec Pharma, Johnson & Johnson, Merck & Co., and Seres Therapeutics, where he oversaw its NASDAQ IPO. His work has contributed to the development of 14 approved drugs targeting conditions including HIV, HCV, tuberculosis, CMV, and C. difficile, and he has completed over 160 business development, licensing, and partnership transactions across more than 20 therapeutic areas. He previously chaired the FDA's Antiviral Advisory Committee, serves on the Corporate Advisory Board of the Carey Business School at Johns Hopkins University, and has published over 300 papers on HIV and other infectious diseases.
Board director at VerImmune
Intro paths
→
In turn, ROGER can intro founders to VerImmune's investors below.
VerImmune's investors · 5
__Twitter.png)
Co-founders at VerImmune
JW
JOSHUA WANGExecutive Officer, Director, Promoter
Director at Rubius Therapeutics
Intro paths
→
In turn, ROGER can intro founders to Rubius Therapeutics's investors below.
Rubius Therapeutics's investors · 3
Executive at Seres Therapeutics
Intro paths
→
In turn, ROGER can intro founders to Seres Therapeutics's investors below.
Experience
- 1E TherapeuticsMember Board of Directorscurrent2025 — presentIsrael
- Indaptus Therapeutics Inc.Founding Chairman of the Board of Directorscurrent2021 — presentSan Diego County, California, United States
- Seres TherapeuticsSenior Clinical Advisor to the Board of Directorscurrent2019 — presentCambridge, Massachusetts
- Seres TherapeuticsFounding Chairman of the Board of Directors2013 — 2019Cambridge, Massachusetts
- Seres TherapeuticsPresident, CEO and Chairman2014 — 2019Cambridge, MA
- OM PharmaSenior Strategic Advisorcurrent2021 — presentGeneva, Switzerland
- VerImmuneFounding Director, of the Board of Directorscurrent2020 — presentBoston, Massachusetts
- Pomerantz Life Sciences Consulting Group, LLCPresidentcurrent2013 — presentGreater Philadelphia Area
- CollPlantChairman Of The Board Of Directors2020 — 2026Rehovot Area, Israel
- Enlivex Therapeutics (Nasdaq: ENLV)Vice Chairman of the Board2023 — 2025Israel
- Viracta Therapeutics, Inc.Chairman of the Board Of Directors2020 — 2025San Diego County, California, United States
- ContraFect CorpPresident, CEO and Chairman2019 — 2023Yonkers, New York
- ContraFect CorpPresident, CEO, and Chairman2014 — 2023Yonkers, NY
- X-Vax Technology, Inc.Founding Director, Board Of Directors2019 — 2023Greater New York City Area
- Silicon TherapeuticsFounding Chairman, Board of Directors2019 — 2022Cambridge, Massachusetts
- Aridis PharmaceuticalsChairman of the Scientific Advisory Board2016 — 2022San Francisco Bay Area
- Ring Therapeutics, Inc.Senior Virology Adviser2019 — 2021Cambridge, Massachusetts
- PathoVax LLCSenior Consultant to the Board of Directors2015 — 2021
- Rubius TherapeuticsFounding Director, Board of Directors2014 — 2019Cambridge, MA
- Flagship PioneeringVenture Partner2014 — 2019Cambridge, MA
- InnaVirVaxSenior Advisor to the Board of Directors2015 — 2018Greater Paris Metropolitan Region
- Evelo TherapeuticsFounding Director, Board of Directors2015 — 2016Cambridge, Massachusetts
- Novira TherapeuticsChairman of the Scientific Advisory Board and Senior Advisor to the Board of Directors2013 — 2015Doylestown, PA
Skills & more
Retrovirology2Pharmaceutical Discovery and Development2Business Development and Strategy6Virology27Molecular Biology24Biomedicine3Infectious Diseases93Pharmaceuticals1Published over 300 scientific articles and three books1Member and Chaired the Antiviral Advisory Panel at the FDA for 5 years1Board Certified in Infectious Diseases and Internal Medicine1Clinical Development27
+12 more
Drug DiscoveryPharmaceutical IndustryVaccinesFDALeadershipBiotechnologyLifesciencesDrug DevelopmentClinical ResearchClinical TrialsMedicineRegulatory Affairs- Medical License — State of Pennsylvania
- Infectious Diseases — Infectious Diseases Society of America
- Internal Medicine — Board of Internal Medicine
From ROGER's professional profile.
Frequently asked questions
- Who is ROGER POMERANTZ?
- Roger Pomerantz is a member of the board of directors at 1E Therapeutics and has held roles at Tibotec Pharma, Johnson & Johnson, Merck & Co., and Seres Therapeutics, where he oversaw its NASDAQ IPO. His work has contributed to the development of 14 approved drugs targeting conditions including HIV, HCV, tuberculosis, CMV, and C. difficile, and he has completed over 160 business development, licensing, and partnership transactions across more than 20 therapeutic areas. He previously chaired the FDA's Antiviral Advisory Committee, serves on the Corporate Advisory Board of the Carey Business School at Johns Hopkins University, and has published over 300 papers on HIV and other infectious diseases.
- Where does ROGER POMERANTZ work?
- ROGER POMERANTZ is Board director at VerImmune and Executive at Seres Therapeutics.
- Where did ROGER POMERANTZ go to school?
- ROGER POMERANTZ studied at Harvard Medical School - Massachusetts General Hospital (Chief Resident, Medicine); Massachusetts Institute of Technology (Post Doctoral Fellowship - Whitehead Institute of Biomedical Research of MIT, Molecular Virology: First Molecular Model of HIV Latency (Cell 1990)); Harvard Medical School (Instructor in Medicine and Pediatrics, Virology).
Same school
Also attended Harvard Medical School - Massachusetts General Hospital12
Barry SteinVice President, Chief Clinical Innovation Officer and Chief Medical Informatics Officer at Flare Capital PartnersHagai Marmor-KolletAssociate at aMoonJeno GyurisPartner at Cure VenturesBill FristCo-Founder and Partner at Frist Cressey VenturesAsh ZenoozVenture Partner at Aegis VenturesBill Frist, M.D.Co-Founder and Partner at Frist Cressey Ventures
+ 6 more
Also attended Massachusetts Institute of Technology2,000
Fred WilsonCo-founder & Partner at Union Square VenturesElad GilSolo general partner investing through Gil CapitalAileen LeeFounder & Managing Partner of Cowboy VenturesHemant TanejaCEO & Managing Director of General CatalystPhilippe LaffontFounder & CIO of Coatue ManagementNat FriedmanCo-lead of Meta Superintelligence Labs; co-founder of NFDG
+ 1,994 more
Also attended Harvard Medical School282
Niko BonatsosFounder and Managing Partner of VerdictAnthony PhilippakisInvestor at GV (Google Ventures)Ben RobbinsInvestor at GV (Google Ventures)David ReshefInvestor at GV (Google Ventures)Krishna YeshwantInvestor at GV (Google Ventures)Morgan CheathamPartner and Head of Healthcare and Life Sciences at Breyer Capital
+ 276 more
Also attended The Johns Hopkins University School of Medicine68
Hal PazInvestor at Khosla VenturesRochelle WalenskyExecutive Partner at Flare Capital PartnersBeth SeidenbergFounding Managing Director at Westlake Village BioPartnersStephen P. ZacharyManaging Partner at Sands Capital VenturesS.K. LeeExecutive Coach at Roble VenturesEric HsuAnalyst, Private Equity at Sofinnova Ventures
+ 62 more
